{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:30:07Z","timestamp":1789662607555,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100210","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:14:44Z","timestamp":1626203684000},"page":"100210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"K.","family":"Oiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tsurumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2021.100210_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100210_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100210_bib3","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/annonc\/mdy184","article-title":"Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study","volume":"29","author":"W\u00e4sterlid","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100210_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100210_bib5","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2019.234435","article-title":"Impact of relative dose intensity of standard regimens on survival in elderly patients aged 80 years and older with diffuse large B-cell lymphoma","volume":"105","author":"Lee","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100210_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100210_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428194.2016.1211279","article-title":"The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"58","author":"Kanemasa","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.esmoop.2021.100210_bib8","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.esmoop.2021.100210_bib9","volume":"Vol 2","author":"Swerdlow","year":"2017"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100210_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/cam4.1973","article-title":"Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on (18) F-FDG PET\/CT in newly diagnosed patients with diffuse large B-cell lymphoma","volume":"8","author":"Senjo","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100210_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-011-1363-4","article-title":"Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens","volume":"91","author":"Goto","year":"2012","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100210_bib12","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00277-014-2031-2","article-title":"Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era","volume":"93","author":"Dalia","year":"2014","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.esmoop.2021.100210_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2021.100210_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24819","article-title":"Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"92","author":"Saygin","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100210_bib15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00277-018-3273-1","article-title":"Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma","volume":"97","author":"Kanemasa","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100210_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100210_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","article-title":"Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients","volume":"82","author":"Bouillanne","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100210_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","article-title":"Performance of two geriatric screening tools in older patients with cancer","volume":"32","author":"Kenis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100210_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/onco.13641","article-title":"Utility of the Geriatric 8 for the prediction of therapy-related toxicity in older adults with diffuse large B-cell lymphoma","volume":"26","author":"Oiwa","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100210_bib20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hon.2524","article-title":"R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial","volume":"36","author":"Hara","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.esmoop.2021.100210_bib21","series-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009 (v4.03: June 14, 2010.)","year":"2010"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100210_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/sim.4780030106","article-title":"A\u00a0non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias","volume":"3","author":"Simon","year":"1984","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100210_bib23","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1097\/CCM.0b013e3181b7fbbb","article-title":"Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies","volume":"37","author":"Shintani","year":"2009","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100210_bib24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.esmoop.2021.100210_bib25","series-title":"Computing RFfS. R: A Language and Environment for Statistical Computing","year":"2016"},{"issue":"18","key":"10.1016\/j.esmoop.2021.100210_bib26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100210_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100210_bib28","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2021.100210_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2018-99-116845","article-title":"No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the International Phase III GOYA study","volume":"132","author":"Sehn","year":"2018","journal-title":"Blood"},{"issue":"9797","key":"10.1016\/j.esmoop.2021.100210_bib30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(11)61176-8","article-title":"Population ageing and wellbeing: lessons from Japan's long-term care insurance policy","volume":"378","author":"Tamiya","year":"2011","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292100171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:18Z","timestamp":1761856038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292100171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S205970292100171X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100210","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic impact of six versus eight cycles of standard regimen in patients with diffuse large B-cell lymphoma: propensity score-matching analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100210"}}